Hypermethylation of the PITX2 promoter, resulting in decreased PITX2 expression, has predicted survival[317,318], but has also been associated with poor prognosis[307,319], and is a prospective prognostic biomarker for prostate cancer[320]. This evidence concerns the gene PITX2 and prostate carcinoma.